2-(2-Ethyl-phenyl)-1-methyl-pyrrolidine | 75633-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(2-Ethyl-phenyl)-1-methyl-pyrrolidine
• 英文别名: 2-(2-Ethylphenyl)-1-methylpyrrolidine
• CAS: 75633-53-3
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: XCGXOAGSOMHTEU-UHFFFAOYSA-N

物化性质

• 沸点：
  258.5±19.0 °C(Predicted)
• 密度：
  0.962±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-Ethyl-phenyl)-1-methyl-pyrrolidine 、 碘甲烷 生成 2-(2-ethylphenyl)-1,1-dimethylpyrrolidin-1-ium;iodide
  参考文献：
  名称：

  SEEMAN J. I.; SECOR H. V.; HARTUNG H.; GALZERANO R., J. AMER. CHEM. SOC., 1980, 102, NO 26, 7741-7747

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(2-Ethylphenyl)pyrrolidine 生成 2-(2-Ethyl-phenyl)-1-methyl-pyrrolidine
  参考文献：
  名称：

  SEEMAN J. I.; SECOR H. V.; HARTUNG H.; GALZERANO R., J. AMER. CHEM. SOC., 1980, 102, NO 26, 7741-7747

  摘要：

  DOI：

文献信息

• CONTROLLED RELEASE PREPARATION
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160128945A1

  公开（公告）日：2016-05-12

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  提供了一种受控释放制剂，其中活性成分的释放受到控制，通过在胃肠道内停留或缓慢迁移来延长时间释放活性成分，采用胶囊化片剂、颗粒或细颗粒的方式，其中活性成分的释放受到控制，并且使用了一种凝胶形成聚合物。所述的片剂、颗粒或细颗粒在含有活性成分的核心颗粒上形成了一个受控释放的涂层。
• [EN] COMPOUNDS AS BCL-2 INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE BCL-2
  申请人：FOCHON PHARMACEUTICALS LTD

  公开号：WO2021223736A1

  公开（公告）日：2021-11-11

  Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

  提供了特定的Bcl-2抑制剂，其药物组成物以及使用方法。
• METHOD FOR PRODUCING GRANULES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1852100A1

  公开（公告）日：2007-11-07

  In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50°C or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

  在含有生物活性物质的颗粒的生产过程中，通过将颗粒的温度加热至约 50°C 或更高，并保持温度约 1 分钟或更长时间，可减少生物活性物质洗脱曲线的变化。将含有生物活性物质的主剂的喷雾剂喷洒到芯上的同时，将喷雾速度设定为每 1 克芯约 90 毫克/分钟或更高，并将离心流化床包衣造粒机的单位面积总喂料重量设定为约 1.5 克/平方厘米或更高，可减少颗粒中生物活性物质洗脱曲线的变化。
• Controlled release preparation
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2277510A2

  公开（公告）日：2011-01-26

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  一种可控制有效成分释放的控释制剂，可通过在胃肠道内停留或缓慢迁移来延长有效成分的释放时间，其方法包括将可控制有效成分释放的片剂、颗粒剂或细颗粒剂与凝胶形成聚合物胶囊化。所述片剂、颗粒剂或细颗粒剂在含有活性成分的核心颗粒上形成一层可控制释放的包衣层。
• DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1602362B1

  公开（公告）日：2016-09-28